Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Sep 29, 2023 12:05pm
110 Views
Post# 35661847

October

OctoberAs we move through the last day of trading in September we look forward to October with some apprehension.

I think we can all assume this Arbitration will conclude this coming month.  The question is when.
I don't think the Arbitrator(s) will allow this to go beyond the 2 year mark (Oct. 18th).
With that in mind the countdown begins. In my opinion contrary to others here there will not be a deal struck between Replicel and Shiseido.  If they were working on a deal we would have heard by now.  Wy risk the Arbitraitor(s) rendering their judgement while a deal is being formulated.

Well fellow Replicel shareholders and bloggers here on Stockhouse I wish you all the best as we wait.
<< Previous
Bullboard Posts
Next >>